Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617303 | 0.83 | MEN1 (0.42) | OPRL1TDP1 | |
| SCHEMBL3605818 | 0.79 | SLC6A2 (0.38) | OPRL1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3604966 | 0.79 | MEN1 (0.39) | MGLLOPRL1KDM4EALDH1A1MAPT | |
| SCHEMBL3600126 | 0.79 | MGLL (0.39) | MGLLOPRL1ADRB1ALOX5KDM4E | |
| SCHEMBL3596885 | 0.78 | PTPN1 (0.41) | OPRL1KDM4ERECQLSLC6A2OPRM1 | |
| SCHEMBL4064146 | 0.77 | MAPT (0.40) | MGLLOPRL1ADRB1ALOX5KDM4E | |
| SCHEMBL3599855 | 0.77 | TP53 (0.42) | OPRL1KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL3604961 | 0.77 | CA12 (0.39) | OPRL1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4056735 | 0.76 | POLB (0.41) | OPRL1KDM4EALDH1A1MAPTRECQL | |
| SCHEMBL3605620 | 0.75 | PDE7A (0.40) | OPRL1KDM4ERECQLOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-7601722-B2 | Aryl sulfamide derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080194654-A1 | HYDROXY-SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | MGLL 1985/4885OPRL1 53/4885ADRB1 123/4885 |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | MGLL 697/4885OPRL1 55/4885ADRB1 115/4885 |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | MGLL 1985/4885OPRL1 53/4885ADRB1 123/4885 |
| US-20080194654-A1 | HYDROXY-SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, TPH1 | MGLL 1576/4885OPRL1 47/4885ADRB1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.